MedTrace Logo

Study in Healthy Males to Assess Bioavailability of Single Fostamatinib With iv Micro Tracer Dose

NCT01598571 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2012-08-22

No results posted yet for this study

Summary

Study in healthy males to assess bioavailability of single fostamatinib with iv micro tracer dose.

Conditions

  • Healthy

Interventions

DRUG

Fostamatinib

Fostamatinib 50 mg tablet

DRUG

Fostamatinib

Fostamatinib 100 μg \[14C\] R406 intravenous micro tracer dose

Sponsors & Collaborators

Principal Investigators

  • Mark Layton, MD · AstraZeneca, Alderley Park

  • Sharan Sidhu, MB CHB, BAO, MRCS · Quotient Clinical Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01598571 on ClinicalTrials.gov